Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. reports developments in molecular diagnostics, including its patented platform for designing molecular diagnostic tests and its Co-Dx PCR platform. Company news commonly covers clinical and regulatory disclosures, commercialization activity through CoSara and CoMira joint ventures, intellectual property and technology updates, and operating and financial results.
Recurring updates also include material agreements, governance matters, capital-structure actions, and securities-listing developments. The company’s public disclosures connect its diagnostic-test pipeline, platform development, and commercialization strategy with financing, shareholder approvals, and other corporate actions.
Co-Diagnostics (Nasdaq: CODX) completed clinical and analytical performance studies for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro instrument. Over 1,400 patients were enrolled at 9 U.S. sites, with 27 analytical studies and more than 10,000 PCR test cup runs. Data are intended to support a Dual FDA 510(k) and CLIA Waiver by Application submission for point-of-care use, targeted for Q3 2026. The platform remains subject to regulatory review and is not yet available for sale.
Co-Diagnostics (Nasdaq: CODX) reported that its Vector Smart mosquito abatement district customer base now spans 21 states, with four new full laboratory installs in June 2026. The expansion aligns with a Co-Dx webinar for prospective MAD customers during National Mosquito Control Awareness Week.
Vector Smart multiplex PCR tests target West Nile, multiple encephalitis viruses, Zika, dengue and chikungunya, supporting decentralized, in-house PCR testing and faster vector-borne disease surveillance for communities.
Co-Diagnostics (Nasdaq: CODX) hosted a delegation from joint venture partner CoMira Diagnostics from the Kingdom of Saudi Arabia for a week-long visit and June 17, 2026 event unveiling a future automated PCR test kit manufacturing line.
The planned technology transfer aims to bring Co-Dx's AI-enabled molecular diagnostics platform and scalable manufacturing capabilities to KSA and 18 other Middle Eastern and Northern African countries.
Co-Diagnostics (Nasdaq: CODX) signed an exclusive distribution agreement with its longstanding Mexico partner for the Co-Dx™ PCR point-of-care platform, including PCR Pro® and related test kits. The deal extends the relationship five years and supports Latin American commercialization ahead of required regulatory authorizations.
The partner has generated over $18 million in revenue for Co-Diagnostics since 2020 through Logix Smart® PCR tests and lab equipment sales. Logix Smart COVID-19 PCR tests accounted for over 50% of Mexico’s COVID-19 tests through 2021, based on public data.
Co-Diagnostics (Nasdaq: CODX) and joint venture CoSara reported progress in developing Ebola PCR tests and expanding the Co-Dx™ PCR point-of-care platform.
The program includes a pan-Ebola assay to detect multiple ebolavirus species and a multiplex assay to differentiate Sudan, Taï Forest, Zaire, and Bundibugyo strains, with planned point-of-care, blood-based testing on Co-Dx PCR Pro®, all subject to further development and regulatory review.
Co-Diagnostics (Nasdaq: CODX) announced an advanced PCR assay development strategy for Bundibugyo virus (BDBV), the ebolavirus strain driving the 2026 outbreak in DRC and Uganda. Partnering with joint venture CoSara, the plan targets faster international deployment, pan-Ebola detection options, and support for point-of-care PCR workflows, subject to regulatory review.
Co-Diagnostics (Nasdaq: CODX) entered a securities purchase agreement for a $3.0 million private placement priced at-the-market under Nasdaq rules. The deal covers common stock or pre-funded warrants plus accompanying warrants.
The offering includes immediate-exercise five-year warrants and is expected to close on or about May 21, 2026.
Co-Diagnostics (Nasdaq: CODX) announced completion of its assay development strategy for Bundibugyo virus (BDBV), linked to the current Ebola outbreak in the Democratic Republic of the Congo and Uganda.
The company plans to use its Co-Dx PCR point-of-care platform, which remains under regulatory review and not yet for sale.
Co-Diagnostics (Nasdaq: CODX) reported Q1 2026 revenue of $0.15 million, up from $0.05 million in Q1 2025. Operating expenses were $9.2 million and net loss was $9.1 million, or $4.06 per share. Cash was $8.2 million on March 31, 2026.
Key updates include an Indian CDSCO license and ISO 13485 certification for the CoSara PCR Pro® instrument, South Asia territory expansion lifting TAM to about $13 billion, completion of upper respiratory clinical enrollment, TB study preparations in India, and advancement of a CoMira manufacturing facility in Saudi Arabia.
Co-Diagnostics (Nasdaq: CODX) joint venture CoMira has finalized a lease for a ~14,400 sq ft turnkey manufacturing facility in Sudair Industrial City, Saudi Arabia, advancing localized production of PCR instruments, laboratory equipment and medical consumables.
The lease follows an approved industrial land allocation and aims to support capital-efficient operational readiness, regional distribution across KSA and MENA, and alignment with Saudi Vision 2030, subject to required regulatory clearances.